JP7382316B2 - ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用 - Google Patents

ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用 Download PDF

Info

Publication number
JP7382316B2
JP7382316B2 JP2020526547A JP2020526547A JP7382316B2 JP 7382316 B2 JP7382316 B2 JP 7382316B2 JP 2020526547 A JP2020526547 A JP 2020526547A JP 2020526547 A JP2020526547 A JP 2020526547A JP 7382316 B2 JP7382316 B2 JP 7382316B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
antigen
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020526547A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502988A5 (https=
JP2021502988A (ja
Inventor
レヴィ，オファー
ジェイ． ドウリング，デイヴィッド
ボリーロ，フランセスコ
エー． スコット，デイヴィッド
イー． ブライトマン，スペンサー
フェル，フレデリク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2021502988A publication Critical patent/JP2021502988A/ja
Publication of JP2021502988A5 publication Critical patent/JP2021502988A5/ja
Priority to JP2023131871A priority Critical patent/JP2023175686A/ja
Application granted granted Critical
Publication of JP7382316B2 publication Critical patent/JP7382316B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0291—Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/20—Rubella virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
JP2020526547A 2017-11-14 2018-11-14 ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用 Active JP7382316B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023131871A JP2023175686A (ja) 2017-11-14 2023-08-14 ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762586137P 2017-11-14 2017-11-14
US62/586,137 2017-11-14
PCT/US2018/061135 WO2019099578A1 (en) 2017-11-14 2018-11-14 Use of imidazopyrimidine for modulating human immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023131871A Division JP2023175686A (ja) 2017-11-14 2023-08-14 ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用

Publications (3)

Publication Number Publication Date
JP2021502988A JP2021502988A (ja) 2021-02-04
JP2021502988A5 JP2021502988A5 (https=) 2021-12-23
JP7382316B2 true JP7382316B2 (ja) 2023-11-16

Family

ID=66539100

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020526547A Active JP7382316B2 (ja) 2017-11-14 2018-11-14 ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用
JP2023131871A Pending JP2023175686A (ja) 2017-11-14 2023-08-14 ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023131871A Pending JP2023175686A (ja) 2017-11-14 2023-08-14 ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用

Country Status (6)

Country Link
US (1) US11730810B2 (https=)
EP (1) EP3710007A4 (https=)
JP (2) JP7382316B2 (https=)
KR (2) KR102775718B1 (https=)
CN (1) CN111587114A (https=)
WO (1) WO2019099578A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7304855B2 (ja) 2017-11-14 2023-07-07 ザ チルドレンズ メディカル センター コーポレーション 新規イミダゾピリミジン化合物およびそれらの使用
CN111587114A (zh) * 2017-11-14 2020-08-25 儿童医学中心公司 用于调节人免疫应答的咪唑并嘧啶的用途
EP4277650A4 (en) * 2021-01-15 2025-05-14 The Board of Trustees of the Leland Stanford Junior University Adjuvants to stimulate broad and persistent innate immunity against various antigens
WO2024151501A1 (en) * 2023-01-09 2024-07-18 The Children's Medical Center Corporation Novel imidazopyrimidine compound and uses thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003513977A (ja) 1999-11-10 2003-04-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換２−アリール−３−（ヘテロアリール）−イミダゾ［１，２−α］ピリミジン類および関連薬剤組成物および方法
WO2006029223A2 (en) 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
JP2009503112A (ja) 2005-08-04 2009-01-29 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節化合物としてのイミダゾ［２，１−ｂ］チアゾール誘導体
JP2014500331A (ja) 2010-12-22 2014-01-09 ヘングルイ（ユーエスエイ），リミテッド ２−アリールイミダゾ［１，２−ｂ］ピリダジン、２−フェニルイミダゾ［１，２−ａ］ピリジンおよび２−フェニルイミダゾ［１，２−ａ］ピラジン誘導体
US20140275119A1 (en) 2013-03-15 2014-09-18 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
JP2015526412A (ja) 2012-07-19 2015-09-10 南京インパクト薬業有限会社Ｉｍｐａｃｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヘッジホッグ経路阻害剤としてのｎ−（３−ヘテロアリールアリール）−４−アリールアリールカルボキサミド及び類似体並びにそれらの使用
JP2016503029A (ja) 2012-12-13 2016-02-01 アデュロ バイオテック，インコーポレイテッド 明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法
JP2016539982A (ja) 2013-12-09 2016-12-22 ユーシービー バイオファルマ エスピーアールエル Ｔｎｆ活性のモジュレーターとしてのイミダゾピリミジン誘導体
US20170158724A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Novel Compounds

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69524598T2 (de) 1994-06-20 2002-07-11 Takeda Chemical Industries, Ltd. Kondensierte imidazolderivate, ihre herstellung und verwendung
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
EP1294723A1 (en) 2000-05-24 2003-03-26 MERCK SHARP & DOHME LTD. 3-phenyl-imidazo-pyrimidine derivatives as ligands for gaba receptors
GB0128499D0 (en) * 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
EP1737459B1 (en) 2004-03-19 2009-08-05 Warner-Lambert Company LLC Imidazopyridine and imidazopyrimidine derivatives as antibacterial agents
BRPI0513811A (pt) 2004-07-27 2008-07-15 Gilead Sciences Inc imidazo [4,5-d] pirimidinas, seus usos e processos de preparação
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1955077B1 (en) * 2005-12-02 2012-06-13 Sirtris Pharmaceuticals, Inc. Mass spectrometry assays for acetyltransferase/deacetylase activity
WO2008027812A2 (en) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
ME02372B (me) 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
RU2364597C1 (ru) 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
EP2103614A1 (en) 2008-03-18 2009-09-23 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
FR2933982A1 (fr) 2008-07-18 2010-01-22 Sanofi Aventis Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
US8962652B2 (en) * 2009-10-22 2015-02-24 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
EP2958889B1 (en) 2013-02-25 2017-03-22 The Scripps Research Institute Neoseptins: small molecule adjuvants
AU2014224976B2 (en) * 2013-03-05 2017-09-28 Merck Patent Gmbh 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
UY35400A (es) * 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
CN103467590B (zh) * 2013-09-02 2016-04-13 深圳大学 生物偶联体、制备其的嘌呤类化合物、合成方法、药用制剂以及其在免疫调节中的应用
RU2725979C2 (ru) 2014-06-25 2020-07-08 Ф. Хоффманн-Ля Рош Аг ИМИДАЗО[1,2-а]ПИРАЗИН-1-ИЛ-БЕНЗАМИДЫ ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ
WO2016148114A1 (ja) 2015-03-13 2016-09-22 国立大学法人北海道大学 酸化ストレス誘導神経細胞死抑制化合物
CN111587114A (zh) * 2017-11-14 2020-08-25 儿童医学中心公司 用于调节人免疫应答的咪唑并嘧啶的用途
JP7304855B2 (ja) * 2017-11-14 2023-07-07 ザ チルドレンズ メディカル センター コーポレーション 新規イミダゾピリミジン化合物およびそれらの使用

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003513977A (ja) 1999-11-10 2003-04-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換２−アリール−３−（ヘテロアリール）−イミダゾ［１，２−α］ピリミジン類および関連薬剤組成物および方法
WO2006029223A2 (en) 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
JP2009503112A (ja) 2005-08-04 2009-01-29 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節化合物としてのイミダゾ［２，１−ｂ］チアゾール誘導体
JP2014500331A (ja) 2010-12-22 2014-01-09 ヘングルイ（ユーエスエイ），リミテッド ２−アリールイミダゾ［１，２−ｂ］ピリダジン、２−フェニルイミダゾ［１，２−ａ］ピリジンおよび２−フェニルイミダゾ［１，２−ａ］ピラジン誘導体
JP2015526412A (ja) 2012-07-19 2015-09-10 南京インパクト薬業有限会社Ｉｍｐａｃｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヘッジホッグ経路阻害剤としてのｎ−（３−ヘテロアリールアリール）−４−アリールアリールカルボキサミド及び類似体並びにそれらの使用
JP2016503029A (ja) 2012-12-13 2016-02-01 アデュロ バイオテック，インコーポレイテッド 明確な立体化学を有する環状プリンジヌクレオチドを含む組成物ならびにそれらの調製および使用方法
US20140275119A1 (en) 2013-03-15 2014-09-18 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
JP2016539982A (ja) 2013-12-09 2016-12-22 ユーシービー バイオファルマ エスピーアールエル Ｔｎｆ活性のモジュレーターとしてのイミダゾピリミジン誘導体
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
US20170158724A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Novel Compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACS Med. Chem. Lett.，2015年，Vol.6，p.249-253
Bioorganic & Medicinal Chemistry Letters，2016年，Vol.26，p.4246-4249

Also Published As

Publication number Publication date
US11730810B2 (en) 2023-08-22
EP3710007A1 (en) 2020-09-23
JP2023175686A (ja) 2023-12-12
WO2019099578A8 (en) 2019-06-20
WO2019099578A1 (en) 2019-05-23
CN111587114A (zh) 2020-08-25
JP2021502988A (ja) 2021-02-04
KR102775718B1 (ko) 2025-03-06
KR20200088398A (ko) 2020-07-22
KR20250030535A (ko) 2025-03-05
US20200282048A1 (en) 2020-09-10
EP3710007A4 (en) 2021-12-15

Similar Documents

Publication Publication Date Title
US20250325659A1 (en) Use of toll-like receptor 2 (tlr-2) agonist for modulating human immune response
JP2023175686A (ja) ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用
JP7304855B2 (ja) 新規イミダゾピリミジン化合物およびそれらの使用
JP7675070B2 (ja) 治療、特にｍｙｄ８８変異疾患における使用のためのｈｃｋ阻害剤としてのピラゾロピリミジン誘導体
JP7821573B2 (ja) Ｄｏｔ１ｌディグレーダーおよびその使用
US11633473B2 (en) Stimulator of Interferon Genes (STING) ligands and uses thereof
US12611456B2 (en) Use of thiazole amide compounds for modulating human immune response
US9714265B2 (en) Mutagenic nucleoside analogs and uses thereof
US20230201339A1 (en) Use of thiazole amide compounds for modulating human immune response
EP3908583B1 (en) Dot1l degraders and uses thereof
US20250041278A1 (en) Tlr8 agonist for modulating immune response
WO2025151620A1 (en) Functionalized imidazopyrimidine compounds and uses thereof
US20250000971A1 (en) Tlr4 agonist for modulating immune response
WO2024151501A1 (en) Novel imidazopyrimidine compound and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230905

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231012

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231106

R150 Certificate of patent or registration of utility model

Ref document number: 7382316

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150